



The Board of Lumito AB has decided to move the Annual General Meeting to 4 June

The Board of Lumito has decided to move the annual general meeting from 22 May to 4 June. The reason for the postponement is that the annual general meeting otherwise would have taken place in the middle of the subscription period for the new rights issue, as suggested by the Board. A notice convening the annual general meeting will be published no later than 3 May 2019.

For more information, please contact:

Stefan Nilsson, CEO of Lumito Telephone: +46 767 78 59 05
Email: sn@lumito.se

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents.

Lumito's share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.